Alice Zhang (Verge Genomics)
July 8, 2021 06:30 AM EDT
Deals

Eli Lil­ly makes mod­est bet on 'all-in-hu­man' dis­cov­ery out­fit for ALS drugs, deep­en­ing bid in pre­ci­sion neu­rol­o­gy

Kyle Blankenship

For years, Big Phar­ma has re­treat­ed from neu­rol­o­gy amid a se­ries of high-pro­file fail­ures in the big-tick­et in­di­ca­tions such as Alzheimer’s and ALS. But the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times